ALK-Abelló A/S

Research ALK-Abelló A/S (ALK-B) on Bullrun: valuation model: 5.5% overvalued, market cap DKK 56.46B, P/E 43.9, dividend yield 0.6%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerALK-B
• ExchangeCO
• CountryDenmark
• SectorHealthcare
• IndustryBiotechnology
• CurrencyDKK
• Valuation signal5.5% overvalued
• Market capDKK 56.46B
• P/E43.9
• Dividend yield0.6%
• Financial periodFY2025
• RevenueDKK 6.31B
• Revenue growth14.0%
• Net incomeDKK 1.20B
• Free cash flowDKK 1.54B
• Gross margin67.1%

Valuation Snapshot

Bullrun's latest valuation model marks ALK-Abelló A/S as 5.5% overvalued; latest market cap is DKK 56.46B; P/E is 43.9; dividend yield is 0.6%.

About ALK-Abelló A/S

ALK-Abelló A/S, an allergy solutions company, develops treatments for respiratory allergy, anaphylaxis, and food allergy and new disease areas in the European Union, the United Kingdom, Norway, Switzerland, the United States, Canada, Japan, China, and internationally.

Frequently asked questions

Is ALK-Abelló A/S overvalued or undervalued?

Bullrun's valuation model currently marks ALK-Abelló A/S as 5.5% overvalued.

What is ALK-Abelló A/S's market cap?

ALK-Abelló A/S's market capitalization is DKK 56.46B.

What is ALK-Abelló A/S's P/E ratio?

ALK-Abelló A/S's price-to-earnings (P/E) ratio is 43.9.

Does ALK-Abelló A/S pay a dividend?

ALK-Abelló A/S has a dividend yield of 0.6%.

What does ALK-Abelló A/S do?

ALK-Abelló A/S, an allergy solutions company, develops treatments for respiratory allergy, anaphylaxis, and food allergy and new disease areas in the European Union, the United Kingdom, Norway, Switzerland, the United States, Canada, Japan, China, and internationally.